Table 3.
Estimated absolute risk difference (percentage points) for any event (recurrence, new tumour or death) between women treated with goserelin and those not treated with goserelin, according to age and whether women took tamoxifen or not.
| Absolute risk difference (95% confidence interval) * | ||||
| No. of years since randomisation | Women who did not take tamoxifen |
Women who took tamoxifen |
||
| Age <40 years (n = 191) | Age ≥ 40 years (n = 754) | Age < 40 years (n = 415) | Age ≥ 40 years (n = 1346) | |
| 5 | −3.6 (−15.0 to +10.1) | −11.2 (−15.8 to −6.2) | −4.3 (−11.0 to +3.8) | −1.1 (−4.3 to +2.9) |
| 10 | −4.0 (−17.3 to +10.9) | −13.4 (−19.2 to −7.3) | −5.1 (−13.2 to +4.3) | −1.5 (−6.1 to +3.9) |
| 15 | −4.2 (−18.6 to +11.0) | −14.8 (−21.5 to −7.9) | −5.5 (−14.7 to +4.5) | −1.7 (−7.0 to +4.4) |
| Hazard ratio (95% CI) | 0.89 (0.58–1.35) | 0.65 (0.52–0.80) | 0.86 (0.66–1.13) | 0.95 (0.80–1.14). |
*
If P = the event rate in the ‘no goserelin’ arm at a specified time point, then the absolute risk difference at this time is P minus exp[hazard ratio x logeP].